JOBEN BIO-MEDICAL CO., LTD.
π¨π³China
Orally Administrated JBM-TC4 Prevents Acute Radiodermatitis in Breast Cancer Patients
Phase 2
- Conditions
- Radiodermatitis
- Interventions
- Drug: 3000 mg of PEG-400 per dayDrug: 2000 mg of JBM-TC4 per dayDrug: 3000 mg of JBM-TC4 per day
- First Posted Date
- 2014-11-13
- Last Posted Date
- 2016-06-15
- Lead Sponsor
- Joben Bio-Medical Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT02289365
- Locations
- π¨π³
Department of Oncology, Taipei Verterans General Hospital, Taipei, Taiwan
π¨π³Department of Radiation Oncology, China Medical University Hospital, Taichung, Taiwan
π¨π³Departmant of Radiotherapy, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
Β© Copyright 2025. All Rights Reserved by MedPath